Please try another search
THELMA Therapeutics Co., Ltd. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was KRW 7,704.39 million compared to KRW 3,814.62 million a year ago. Basic loss per share from continuing operations was KRW 133 compared to KRW 148 a year ago. Basic loss per share was KRW 134 compared to KRW 149 a year ago.
Period Ending: | Mar 31, 2023 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 |
---|---|---|---|---|
Total Revenue | 1596.89 | 2212.65 | 2021.13 | |
Gross Profit | 15.69 | 12.58 | 10.51 | |
Operating Income | -1198.43 | -1036.3 | -1083.87 | |
Net Income | -1454.48 | -1414.46 | -1336.65 |
Period Ending: | Mar 31, 2023 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 |
---|---|---|---|---|
Total Assets | 34205.53 | 26903.65 | 10178.37 | |
Total Liabilities | 4157.32 | 15682.32 | 13831.7 | |
Total Equity | 30048.2 | 11221.33 | -3653.32 |
Period Ending: | Mar 31, 2023 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -2422.19 | -599.96 | -414.06 | |
Cash From Investing Activities | 10.28 | 112.48 | -245.95 | |
Cash From Financing Activities | 19934.4 | 486.61 | 460.22 | |
Net Change in Cash | 17522.49 | -0.872 | -199.78 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review